Noora (vaccine)

Noora (vaccine)

Vaccine description
Target	SARS-CoV-2
Vaccine type	Protein subunit
Clinical data
Routes of administration	Intramuscular
Identifiers
CAS Number	2699609-20-4

Part of a series on the
COVID-19 pandemic
COVID-19 (disease) SARS-CoV-2 (virus) Cases Deaths
Timeline 2019 2020 January responses February responses March responses April responses May responses June responses July responses August responses September responses October responses November responses December responses 2021 January responses February responses March responses April responses May responses June responses July responses August responses September responses October responses November responses December responses 2022 January responses February responses March responses April responses May responses June responses July responses August responses September responses October responses November December 2023
Locations By country and territory Africa Antarctica Asia Europe North America Oceania South America By conveyance Cruise ships Naval ships
International response Endemic phase Evacuations Face masks International aid Origin Lockdowns by country Misinformation by governments Fake treatments Social distancing Software Travel United Nations World Health Organization WTO IP waiver Undercounting of deaths COVID-19 apps Zero-COVID National responses Africa China European Union Germany Ghana India Ireland Netherlands New Zealand Nigeria Philippines Russia Sweden UK government US federal government Vietnam
Medical response Disease testing Breathalyzer Development Drug development Drug repurposing Public health mitigation Vaccines History Research VITT Deployment Authorizations Operation Warp Speed Misinformation and hesitancy US Vaccine card Vaccine passports Current vaccines CoronaVac Covaxin Convidecia Janssen Medigen Moderna Novavax Oxford–AstraZeneca Pfizer–BioNTech Sinopharm BIBP Sputnik V
Variants Variants of concern Alpha Beta Gamma Delta Omicron Other variants Epsilon Zeta Eta Theta Iota Kappa Lambda Mu Cluster 5 Lineage B.1.617
Economic impact and recession Arts and culture Aviation Cannabis Cinema films Disney Fashion Financial markets Food industry Food security Journalism Music Performing arts Retail Shipping Television US sportscasting programs Tourism Video games By country Canada India Ireland Malaysia New Zealand Russia UK US By sport Association football Baseball Basketball Combat sports Cricket Disc golf Gaelic games Gridiron football Ice hockey Motorsport Rugby league
Impacts Long COVID Neurological and psychological symptoms Post-exertional malaise Society Animals Alzheimer's disease patients Black people Crime Death rates by country Disability Domestic violence Emergency evacuations Education Female Environment Hospitals Language LGBT community Long-term care Media coverage Mental health Migration Military Notable deaths Other health issues Popular culture Protests Pregnancy Prisons Religion Catholic Church Hajj Science and technology Social media Strikes Suicides Telehealth Xenophobia and racism Politics Diplomacy Ireland Malaysia New Zealand Russia UK US
COVID-19 portal
v t e

Noora (Persian: نورا) is a COVID-19 vaccine candidate developed by Baqiyatallah University of Medical Sciences in collaboration with Plasma Darman Sarv Sepid Co. (lit. White Cypress Plasma Treatment) in Iran.^[1][2] Introduced in June 2021,^[3] it was announced as having "successfully passed the first phase of its clinical trial" two months later.^[4]

The clinical trial reported in the Journal of Medical Virology met a critical scrutiny in May 2023, after which the journal declared it as an invalid study and retracted it in March 2024.^[5][6][7] Independent research in 2024 indicated that the vaccine is very weak (poor immunogenicity and neutralization efficacy) unlikely useful for the later variants of SARS-CoV-2.^[8][9]

Noora vaccine was developed by an Iranian team led by Jafar Salimian and Jafar Amani at the Baqiyatallah University of Medical Sciences in Tehran,^[10] which is supported by the Islamic Revolutionary Guard Corps.^[11] Its design and preparation started in the early 2020 and completed in June 2021. The vaccine with its Phase I clinical trial was officially launched on 27 June 2021.^[12] IRGC Commander-in-Chief Major General Hossein Salami and Health Minister Saeed Namaki officiated the unveiling, and Hossein Samadinia, head of the Baqiyatallah Hospital, received the first dose at the inaugural.^[1][13] Phase I clinical trial involved 70 volunteers and was completed in August 2021.^[4][12]

In March 2022, Hassan Abolqasemi, chancellor of Baqiyatallah University of Medical Sciences, announced that the Phase III clinical trial was completed that involved 10,000 participants.^[14] Soon after which the Iranian Ministry of Health gave it a permit for emergency use, and became the sixth COVID-19 vaccine (after COVIran Barekat, Pasto Covac, Razi Cov Pars, SpikoGen, and FAKHRAVAC) produced in Iran.^[14] The vaccine preparation and preclinical tests in mice, rabbits, and monkeys were reported in the journal Molecular Immunology in September 2022.^[15]

The first clinical trial led by Salimian and Amani,^[10] and supervised by Hassan Abolghasemi and Gholamhossein Alishiri, was published in the Journal of Medical Virology 27 August 2022.^[16] The report claims that the vaccine is effective, safe and capable of providing immunity.^[10] The report concludes:

The results of this Phase 1 trial showed acceptable safety without serious adverse events and significant seroconversions in the humoral and cellular immunity panel. The dose of 80 μg is an appropriate dose for injection in the next phases of the trial.^[16]

Noora vaccine requires three doses given by intramuscular injection on days 0, 21 and 35.^[17] Phase I clinical trial was claimed to indicate successful immunity against SARS-CoV-2 Omicron variant.^[10]

Noora is a recombinant RBD protein subunit vaccine.^[17] It contains three truncated parts of SARS-CoV-2: spike protein, receptor-binding protein and nucleoprotein. The immune response is enhanced by the addition of alum as an adjuvant.^[15][18]

By early 2022, 3 million doses were produced monthly.^[11] As of March 2022, 5 millions doses were produced.^[14]

In May 2023, Donald Forthal, chief of infectious diseases at the University of California, Irvine, wrote a commentary on the Phase I clinical trial paper in the Journal of Medical Virology,^[21] severely criticising the validity of the study.^[22] Forthal pointed out several data inconsistency, misrepresentation, vague experimental methods and conflict of interest that would have used to reject the paper in the first place.^[7][23] He made a concern that "a manuscript containing so many serious flaws would have been accepted for publication following peer review, and given these issues, a retraction may be in order".^[21] As the criticism was posted on PubPeer, other scientists also raised other concerns in the study.^[5][23] Australian epidemiologist Gideon Meyerowitz-Katz stated that the report had several other "impossible" and "contradictory" results.^[7]

While the authors and the Baqiyatallah University remained silent, Journal of Medical Virology's editor-in-chief Shou-Jiang Gao invited justifications from the authors. The authors submitted the rebuttal, but after the third round of peer reviewing, they gave up on the final dateline of 23 November 2023 for revision.^[23] With no further response from the authors, the journal announced retraction of the paper on 2 March 2024,^[7][22] with a note:

The retraction has been agreed due to concerns raised by third parties regarding issues with the data presented in the article. Several inconsistencies concerning the information provided about the analyzed subjects were additionally identified. Furthermore, the authors failed to disclose the presence of potential conflicts of interest that may have affected the interpretation of the results presented. Accordingly, the editors consider the conclusions of this manuscript to be invalid. The authors have been informed of the decision to retract but did not agree with it.^[6]

One of the supervisors of the clinical trial, Abolghasemi claimed that the criticism and retraction were not of scientific causes but of prejudices, and his team was not given a chance for explanation. As he wrote to Retraction Watch: "Retraction of our article was a political decision not a scientific decision because there was a pressure on journal based on [apartheid] scientific issue. Our response to the comment never accepted by [PubPeer] and journal to be published."^[7]

An independent research team from Tehran University of Medical Sciences and Avicenna Research Institute experimentally analysed four COVID-19 vaccines developed in Iran. Their report in Iranian Journal of Immunology, published in March 2024, showed that Noora and SpikoGen do hot have the expected efficacy (as indicated by poor immunogenicity and neutralization efficacy).^[8] As the two vaccines do not provide protection from SARS-CoV-2 Delta variant, it is unlikely useful for the later variants of SARS-CoV-2.^[9]

• Pharmaceuticals in Iran
• COVID-19 pandemic in Iran
• COVID-19 vaccine clinical research

Scholia has a profile for Noora (Q108542111).